PULMONARY FUNCTION TESTS (PFTS) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT AS PREDICTOR OF PULMONARY COMPLICATIONS AND SURVIVAL IN ADULTS WITH HEMATOLOGICAL MALIGNANCIES
(Abstract release date: 05/21/15)
EHA Library. Annibali O. 06/12/15; 103002; PB2050
Disclosure(s): UNIVERSITÀ CAMPUS BIO-MEDICO ROMAEmatologia
Dr. Ombretta Annibali
Contributions
Contributions
Abstract
Abstract: PB2050
Type: Publication Only
Background
Autologous Stem Cell Transplantation (ASCT) represents a standard-of-care for Multiple Myeloma patients eligible to receive high-dose chemotherapy, Lymphoma patients undergoing second-line treatments and for a small proportion of Acute Leukemia patients. Although all canditates to an ASCT are carefully evaluated for their eligibility with a complete screening of clinical, laboratory, imaging and functional tests to check comorbidities, global organ function and infections, pulmonary and infective complications are a significant cause of morbidity and mortality after ASCT. However, the relationship between pre-transplant Pulmonary Function Tests (PFTs), development of post-ASCT complications and mortality is unknown.
Aims
The aim of this study was to evaluate the role of pre ASCT PFTs on post-ASCT complications and mortality
Methods
We collected data for 88 patients undergoing ASCT between March 2008 and February 2015 in our Institution. Complete PFTs were obtained in 62 patients ( 74% males; median age 57 yrs, range, 18-69): Multiple Myeloma n=44, Non-Hodgkin Lymphoma n=18, Hodgkin Lymphoma n=4, Acute Myeloid Leukemia n=1). ASCT was performed as first line treatment in 42 (67%) patients, after first relapse in 17 (28%) and as salvage treatment after ≥2 relapse in 3 (5%). Previous regimens including drugs known to induce pulmonary toxicity, such as bortezomib and bleomycin had been administered to 34/62 (55%) patients
Results
Of the 62 transplanted patients, 9 (13.4%) had abnormal PFTs at baseline (5 obstructive and 4 restrictive PFTs) and 19 (28.4%) had two or more major chronic comorbidities (metabolic and cardiovascular disease). Infective complications occurred in 40/62 (64.5%) and respiratory complications in 9/62 (14.5%) cases. After a median follow-up of 25 months (range, 4-111), 48 out of 62 patients (77,4%) are alive. Post-ASCT respiratory complications were significantly higher (97% vs 83 %; P=0.05) in patients with reduced pre-ASCT FEV1
Summary
Keyword(s): Autologous bone marrow transplant
Session topic: Publication Only
Type: Publication Only
Background
Autologous Stem Cell Transplantation (ASCT) represents a standard-of-care for Multiple Myeloma patients eligible to receive high-dose chemotherapy, Lymphoma patients undergoing second-line treatments and for a small proportion of Acute Leukemia patients. Although all canditates to an ASCT are carefully evaluated for their eligibility with a complete screening of clinical, laboratory, imaging and functional tests to check comorbidities, global organ function and infections, pulmonary and infective complications are a significant cause of morbidity and mortality after ASCT. However, the relationship between pre-transplant Pulmonary Function Tests (PFTs), development of post-ASCT complications and mortality is unknown.
Aims
The aim of this study was to evaluate the role of pre ASCT PFTs on post-ASCT complications and mortality
Methods
We collected data for 88 patients undergoing ASCT between March 2008 and February 2015 in our Institution. Complete PFTs were obtained in 62 patients ( 74% males; median age 57 yrs, range, 18-69): Multiple Myeloma n=44, Non-Hodgkin Lymphoma n=18, Hodgkin Lymphoma n=4, Acute Myeloid Leukemia n=1). ASCT was performed as first line treatment in 42 (67%) patients, after first relapse in 17 (28%) and as salvage treatment after ≥2 relapse in 3 (5%). Previous regimens including drugs known to induce pulmonary toxicity, such as bortezomib and bleomycin had been administered to 34/62 (55%) patients
Results
Of the 62 transplanted patients, 9 (13.4%) had abnormal PFTs at baseline (5 obstructive and 4 restrictive PFTs) and 19 (28.4%) had two or more major chronic comorbidities (metabolic and cardiovascular disease). Infective complications occurred in 40/62 (64.5%) and respiratory complications in 9/62 (14.5%) cases. After a median follow-up of 25 months (range, 4-111), 48 out of 62 patients (77,4%) are alive. Post-ASCT respiratory complications were significantly higher (97% vs 83 %; P=0.05) in patients with reduced pre-ASCT FEV1
Summary
To reduce the risk of respiratory complications after ASCT, these patients might benefit from the use of a reduced intensity conditioning .
Keyword(s): Autologous bone marrow transplant
Session topic: Publication Only
Abstract: PB2050
Type: Publication Only
Background
Autologous Stem Cell Transplantation (ASCT) represents a standard-of-care for Multiple Myeloma patients eligible to receive high-dose chemotherapy, Lymphoma patients undergoing second-line treatments and for a small proportion of Acute Leukemia patients. Although all canditates to an ASCT are carefully evaluated for their eligibility with a complete screening of clinical, laboratory, imaging and functional tests to check comorbidities, global organ function and infections, pulmonary and infective complications are a significant cause of morbidity and mortality after ASCT. However, the relationship between pre-transplant Pulmonary Function Tests (PFTs), development of post-ASCT complications and mortality is unknown.
Aims
The aim of this study was to evaluate the role of pre ASCT PFTs on post-ASCT complications and mortality
Methods
We collected data for 88 patients undergoing ASCT between March 2008 and February 2015 in our Institution. Complete PFTs were obtained in 62 patients ( 74% males; median age 57 yrs, range, 18-69): Multiple Myeloma n=44, Non-Hodgkin Lymphoma n=18, Hodgkin Lymphoma n=4, Acute Myeloid Leukemia n=1). ASCT was performed as first line treatment in 42 (67%) patients, after first relapse in 17 (28%) and as salvage treatment after ≥2 relapse in 3 (5%). Previous regimens including drugs known to induce pulmonary toxicity, such as bortezomib and bleomycin had been administered to 34/62 (55%) patients
Results
Of the 62 transplanted patients, 9 (13.4%) had abnormal PFTs at baseline (5 obstructive and 4 restrictive PFTs) and 19 (28.4%) had two or more major chronic comorbidities (metabolic and cardiovascular disease). Infective complications occurred in 40/62 (64.5%) and respiratory complications in 9/62 (14.5%) cases. After a median follow-up of 25 months (range, 4-111), 48 out of 62 patients (77,4%) are alive. Post-ASCT respiratory complications were significantly higher (97% vs 83 %; P=0.05) in patients with reduced pre-ASCT FEV1
Summary
Keyword(s): Autologous bone marrow transplant
Session topic: Publication Only
Type: Publication Only
Background
Autologous Stem Cell Transplantation (ASCT) represents a standard-of-care for Multiple Myeloma patients eligible to receive high-dose chemotherapy, Lymphoma patients undergoing second-line treatments and for a small proportion of Acute Leukemia patients. Although all canditates to an ASCT are carefully evaluated for their eligibility with a complete screening of clinical, laboratory, imaging and functional tests to check comorbidities, global organ function and infections, pulmonary and infective complications are a significant cause of morbidity and mortality after ASCT. However, the relationship between pre-transplant Pulmonary Function Tests (PFTs), development of post-ASCT complications and mortality is unknown.
Aims
The aim of this study was to evaluate the role of pre ASCT PFTs on post-ASCT complications and mortality
Methods
We collected data for 88 patients undergoing ASCT between March 2008 and February 2015 in our Institution. Complete PFTs were obtained in 62 patients ( 74% males; median age 57 yrs, range, 18-69): Multiple Myeloma n=44, Non-Hodgkin Lymphoma n=18, Hodgkin Lymphoma n=4, Acute Myeloid Leukemia n=1). ASCT was performed as first line treatment in 42 (67%) patients, after first relapse in 17 (28%) and as salvage treatment after ≥2 relapse in 3 (5%). Previous regimens including drugs known to induce pulmonary toxicity, such as bortezomib and bleomycin had been administered to 34/62 (55%) patients
Results
Of the 62 transplanted patients, 9 (13.4%) had abnormal PFTs at baseline (5 obstructive and 4 restrictive PFTs) and 19 (28.4%) had two or more major chronic comorbidities (metabolic and cardiovascular disease). Infective complications occurred in 40/62 (64.5%) and respiratory complications in 9/62 (14.5%) cases. After a median follow-up of 25 months (range, 4-111), 48 out of 62 patients (77,4%) are alive. Post-ASCT respiratory complications were significantly higher (97% vs 83 %; P=0.05) in patients with reduced pre-ASCT FEV1
Summary
To reduce the risk of respiratory complications after ASCT, these patients might benefit from the use of a reduced intensity conditioning .
Keyword(s): Autologous bone marrow transplant
Session topic: Publication Only
{{ help_message }}
{{filter}}